Teleflex (NYSE:TFX) Releases FY22 Earnings Guidance

Teleflex (NYSE:TFX – Get Rating) issued an update on its FY22 earnings guidance on Friday morning. The company provided earnings per share (EPS) guidance of $13.70-14.30 for the period, compared to the consensus estimate of $13.96. The company issued revenue guidance of +2.3-3.8% to ~$2.87-2.92 billion, compared to the consensus revenue estimate of $2.90 billion.Teleflex also updated its FY 2022 guidance to $13.70-$14.30 EPS.

NYSE TFX opened at $288.69 on Friday. The company has a market capitalization of $13.54 billion, a PE ratio of 28.06, a price-to-earnings-growth ratio of 1.91 and a beta of 1.13. Teleflex has a 1-year low of $256.77 and a 1-year high of $428.36. The company has a current ratio of 2.28, a quick ratio of 1.53 and a debt-to-equity ratio of 0.46. The firm’s fifty day simple moving average is $320.39 and its 200-day simple moving average is $324.03.

Teleflex (NYSE:TFX – Get Rating) last issued its quarterly earnings results on Thursday, April 28th. The medical technology company reported $2.88 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.72 by $0.16. The firm had revenue of $641.70 million for the quarter, compared to analyst estimates of $631.89 million. Teleflex had a return on equity of 17.24% and a net margin of 17.31%. The company’s quarterly revenue was up 1.2% compared to the same quarter last year. During the same period in the previous year, the company posted $2.87 earnings per share. As a group, analysts predict that Teleflex will post 13.98 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Wednesday, June 15th. Shareholders of record on Monday, May 16th will be issued a dividend of $0.34 per share. This represents a $1.36 dividend on an annualized basis and a yield of 0.47%. The ex-dividend date of this dividend is Friday, May 13th. Teleflex’s dividend payout ratio (DPR) is presently 13.22%.

Several equities research analysts recently issued reports on the stock. TheStreet downgraded shares of Teleflex from a b- rating to a c+ rating in a research note on Monday. Zacks Investment Research cut shares of Teleflex from a hold rating to a sell rating and set a $373.00 price objective on the stock. in a research note on Friday, April 1st. StockNews.com upgraded shares of Teleflex from a hold rating to a buy rating in a research report on Wednesday, May 11th. Raymond James cut their target price on shares of Teleflex from $391.00 to $370.00 and set an outperform rating on the stock in a research report on Wednesday, February 23rd. Finally, Bank of America assumed coverage on shares of Teleflex in a report on Monday, May 9th. They set a neutral rating and a $315.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of Buy and an average price target of $388.46.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Empirical Financial Services LLC d.b.a. Empirical Wealth Management acquired a new stake in shares of Teleflex in the 1st quarter worth about $206,000. Graham Capital Management L.P. purchased a new stake in Teleflex in the 1st quarter valued at about $256,000. Allstate Corp purchased a new stake in Teleflex in the 1st quarter valued at about $265,000. Toroso Investments LLC increased its stake in Teleflex by 21.9% in the 4th quarter. Toroso Investments LLC now owns 813 shares of the medical technology company’s stock valued at $267,000 after buying an additional 146 shares during the last quarter. Finally, Maverick Capital Ltd. purchased a new stake in Teleflex in the 1st quarter valued at about $268,000. Institutional investors own 92.21% of the company’s stock.

Teleflex Company Profile (Get Rating)

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.

See Also